These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 14577451)

  • 41. The Effects of Intellectual Property Rights on Access to Medicines and Catastrophic Expenditure.
    Jung Y; Kwon S
    Int J Health Serv; 2015; 45(3):507-29. PubMed ID: 26077858
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
    Luo J; Kesselheim AS
    AMA J Ethics; 2016 Jul; 18(7):727-35. PubMed ID: 27437823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
    Xu Z; Chen W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
    Van Puymbroeck RV
    J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity.
    Diependaele L; Cockbain J; Sterckx S
    Dev World Bioeth; 2017 Apr; 17(1):11-21. PubMed ID: 26818105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The high price of "free" trade: U.S. trade agreements and access to medicines.
    Lopert R; Gleeson D
    J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In the high court of South Africa, case no. 4138/98: the global politics of access to low-cost AIDS drugs in poor countries.
    Barnard D
    Kennedy Inst Ethics J; 2002 Jun; 12(2):159-74. PubMed ID: 12476916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Global pharmaceutical development and access: critical issues of ethics and equity.
    Lage A
    MEDICC Rev; 2011 Jul; 13(3):16-22. PubMed ID: 21778954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. UK Commission concludes international patent laws hinder access to medicines in developing countries.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):59. PubMed ID: 14740605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 53. Does the pharmaceutical sector have a coresponsibility for the human right to health?
    Schroeder D
    Camb Q Healthc Ethics; 2011 Apr; 20(2):298-308. PubMed ID: 21435305
    [No Abstract]   [Full Text] [Related]  

  • 54. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benchmarking progress in tackling the challenges of intellectual property, and access to medicines in developing countries.
    Musungu SF
    Bull World Health Organ; 2006 May; 84(5):366-70. PubMed ID: 16710545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intellectual property rights and traditional medicine: policy dilemmas at the interface.
    Timmermans K
    Soc Sci Med; 2003 Aug; 57(4):745-56. PubMed ID: 12821021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.